Category: Wisconsin

Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts

Initial public offerings took a brief summer break the week of Independence Day, but healthcare IPO activity resumed this week as three more companies joined the US public markets. Here’s a recap of the biotech companies that priced IPOs Wednesday evening. —Genmab is different from the other life science companies that joined the public markets … Continue reading “Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts”

Narrowing AI: A Useful Context for AI Innovation, Opportunity, and Investment

I was asked recently if there was a meaningful analog to AI – its pervasiveness, its transformative potential, its power – in the annals of technology, and I answered with a straight face: “Yes. The Wheel. The Printing Press. Electricity. The Internet.” I truly believe AI is going to be that big, if not bigger, … Continue reading “Narrowing AI: A Useful Context for AI Innovation, Opportunity, and Investment”

Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More

The life science and healthcare worlds are vast. We often talk about impact in terms of millions of patients and billions of dollars. But these worlds can be small, too. It seems at times we’re never far removed from any one person, through their published papers, social media connections, friends, colleagues, or people they’ve mentored. … Continue reading “Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More”

Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs

Amgen and Novartis are stopping work on an experimental Alzheimer’s disease drug after an early look at clinical data showed worsening cognitive function in patients. The interim results announced Thursday were part of a pre-planned review of data from two pivotal clinical trials testing the drug, umibecestat. Based on that review, Amgen (NASDAQ: [[ticker:AMGN]]) and … Continue reading “Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs”

Trump Kills His Administration’s Plan to End Secret Drug Rebates

Donald Trump’s criticism of high drug prices began during the 2016 presidential campaign and continued through his presidency, perhaps most famously just before his inauguration when he said that drug companies were “getting away with murder.” This week has underlined the gap between the administration’s rhetoric and results. Most strikingly, the White House said last … Continue reading “Trump Kills His Administration’s Plan to End Secret Drug Rebates”

Record Exit Value for VC-Backed Startups Could Fuel Investment

More than a third of the companies that went public in the first half of this year were backed by venture capital. That, plus robust merger and acquisition activity, set a record for venture-backed exit value—$165.2 billion in money returned to investors—that’s already topped all other full-year totals, according to the latest VentureMonitor, the quarterly … Continue reading “Record Exit Value for VC-Backed Startups Could Fuel Investment”

WI Startup Funding Hit Record in 2018 as VCs Cut Bigger Checks

A record $300 million was invested in Wisconsin ventures last year, as maturing businesses pulled in larger funding rounds. But a continued decrease in the number of firms raising their first outside capital could signal trouble for the state’s pipeline of budding startups. Those are some of the key takeaways from the latest Wisconsin Portfolio, … Continue reading “WI Startup Funding Hit Record in 2018 as VCs Cut Bigger Checks”

How Do YOU Think the Internet Will Evolve? A Sampling of Your Tweets

[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] For my feature article “Special Report 2069: Predicting the Internet’s Next 50 Years,” I asked my Twitter … Continue reading “How Do YOU Think the Internet Will Evolve? A Sampling of Your Tweets”

Future of the Internet: What Scares Networking Pioneer Radia Perlman

[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] Bob Metcalfe co-invented Ethernet, the communications standard still used for most local on-site networking, but Radia Perlman … Continue reading “Future of the Internet: What Scares Networking Pioneer Radia Perlman”

Why Ethernet Inventor Bob Metcalfe is an Internet Optimist

[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] Right alongside Moore’s Law, which describes the exponential growth in computing power since the 1960s, there’s Metcalfe’s … Continue reading “Why Ethernet Inventor Bob Metcalfe is an Internet Optimist”

Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More

As we pause to celebrate the 4th of July, another birthday is top of mind: A third baby whose embryonic DNA was edited by Chinese scientist He Jiankui. As Xconomy reported in November, He hinted about a second pregnancy after his infamous revelation of twins altered with CRISPR gene editing tools. That second pregnancy—a third … Continue reading “Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More”

Q&A: Providence Exec on Bluetree Acquisition, Trends in Health Tech

Providence St. Joseph Health, a Renton, WA-based organization that operates 51 hospitals and 829 clinics across five US states, announced its latest strategic, IT-focused acquisition last week. The company Providence has agreed to purchase—financial terms aren’t being disclosed—is Bluetree Network, a Madison, WI-based consultancy that works with healthcare providers to install and optimize electronic health … Continue reading “Q&A: Providence Exec on Bluetree Acquisition, Trends in Health Tech”

WI Watchlist: Microsoft, Exact Sciences, Shine & MKE Tech Hub

[Updated 7/3/19, 2:25 pm CT. See below.] Before everyone checks out for the Fourth of July holiday, let’s catch up on some recent Wisconsin innovation news: —Shine Medical Technologies has raised $18 million in new funding, a combination of equity and stock options, according to a filing with the SEC. The round could reach $30 … Continue reading “WI Watchlist: Microsoft, Exact Sciences, Shine & MKE Tech Hub”

Ex-Apple UX Guru Don Norman Calls for Replacing the Internet

[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] No one has done more than Donald Norman to teach us that every piece of hardware … Continue reading “Ex-Apple UX Guru Don Norman Calls for Replacing the Internet”

What Is the Future of the Internet? Experts Predict Next 50 Years

[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] It’s a good thing journalists, pundits, and consultants can’t be held liable for the predictions we … Continue reading “What Is the Future of the Internet? Experts Predict Next 50 Years”

What ARPANET’s History Can Teach Us About Cybersecurity

[Editor’s note: This is part of a series examining the internet’s first 50 years and predicting the next half century. Join Xconomy and World Frontiers Forum on July 16 for Net@50, an event exploring the internet’s past and future.] The internet nearly came with built-in caller ID. The year was 1972: three years after the … Continue reading “What ARPANET’s History Can Teach Us About Cybersecurity”

Peter Gabriel Joins Net@50 Lineup; Tix Going Fast for July 16 Event

Legendary rock musician and longtime internet evangelist Peter Gabriel has joined the all-star cast of speakers for Net@50, a historic event celebrating the 50th anniversary of the first net message—while also looking ahead to the internet’s next 50 years. The event, put on by the non-profit World Frontiers Forum in association with Xconomy, takes place … Continue reading “Peter Gabriel Joins Net@50 Lineup; Tix Going Fast for July 16 Event”

As Cities Ban Face Recognition, Body-Cam Firm Axon Also Nixes It

This week’s decision by police equipment manufacturer Axon to forego using facial recognition software in its body cameras follows a string of other actions against the use of face-matching technology by public agencies. They include a pioneering ban in San Francisco last month, and another passed Thursday by the city council of Somerville, MA. What … Continue reading “As Cities Ban Face Recognition, Body-Cam Firm Axon Also Nixes It”

Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More

It was a busy week. If we had to choose a theme, it was all about getting together. Two huge drug companies, AbbVie and Allergan, said they’d be better as one. Two more huge drug companies, Celgene and Bristol-Myers Squibb, learned they would have to leave a big product behind if they want to merge. … Continue reading “Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More”

Providence St. Joseph to Buy Wisconsin Health IT Consultant Bluetree

Providence St. Joseph Health, a large network of hospitals and clinics headquartered in Renton, WA, said Thursday it plans to acquire Bluetree Network, a consultancy that specializes in projects involving electronic health records software. Providence did not say how much it will pay to acquire Madison, WI-based Bluetree in a news release announcing the deal, … Continue reading “Providence St. Joseph to Buy Wisconsin Health IT Consultant Bluetree”

Degreed Raises $75M to Expand in Growing Workforce Training Sector

Degreed, which helps businesses upgrade the skills of their staffers through an online gateway to learning resources, announced Thursday it has raised $75 million to grow the service and expand internationally. San Francisco-based Degreed is among the educational technology companies now classified as “learning experience platforms,’’ because they organize staff participation in skills development training … Continue reading “Degreed Raises $75M to Expand in Growing Workforce Training Sector”

Led by Tech, Healthcare Debuts, IPOs in 2019 Show Positive Returns

Even as Uber, Lyft, and other high-profile initial public offerings underperformed out of the gate, the average share price of companies that have gone public in the US this year is up by almost 33 percent. That’s according to data based on the mean returns of issuers that started trading through June 19, released by … Continue reading “Led by Tech, Healthcare Debuts, IPOs in 2019 Show Positive Returns”

AbbVie to Pay $63B for Allergan to Prepare for Life Without Humira

[Updated, 10:11 am ET, see below.] Pharmaceutical giant AbbVie this morning agreed to acquire Allergan in a $63 billion deal meant to provide the pharmaceutical giant with enough revenue to brace for the loss of patent protection for the world’s top-selling drug. AbbVie (NYSE: [[ticker:ABBV]]) will pay $188.24 per share in cash and stock for … Continue reading “AbbVie to Pay $63B for Allergan to Prepare for Life Without Humira”

Dems and GOP Senators Unite Versus Big Tech on Data Privacy Bills

To hear some people talk, you’d think the age of bipartisan action in Congress was a lost phenomenon of the distant past. But it’s not so, at least when it comes to certain issues. And no one knows it better than the big Silicon Valley tech companies that are the recent targets of proposed bipartisan … Continue reading “Dems and GOP Senators Unite Versus Big Tech on Data Privacy Bills”

Review: Inside the House of Lies at Theranos

Youth. Charm. Fearlessness. Ruthless focus. These can be positive attributes in an entrepreneur, but in a more rational world, technology investors wouldn’t overvalue them. Risk capital would be allocated based mostly on evidence, data, progress towards milestones—in short, on proof. In the real world, of course, proof is hard to come by. Hope, avarice, or … Continue reading “Review: Inside the House of Lies at Theranos”

Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More

[Corrected 6/24/19, 12:08 p.m. See below.] Cancer remains one of the hottest areas for pharma deals and this week saw a big one: Pfizer’s proposed $11.4 billion buyout of Array Biopharma. The announcement comes less than a month after Boulder, CO-based Array announced positive data from a pivotal study of its combination drug in colorectal … Continue reading “Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More”

Four More Through the IPO Door as Life Science Firms Raise $465M

It’s been a strong year for biotech IPOs and Wednesday shaped up to be a particularly busy day as four life science firms debuted on the public markets. So far this year, 72 companies have gone public, according to IPO research firm Renaissance Capital. That total is down 20 percent compared to the same period … Continue reading “Four More Through the IPO Door as Life Science Firms Raise $465M”

WI Watchlist: Aaron Rodgers, Redox, Zywave, Rusinow & More

It’s time to catch up on some recent Wisconsin innovation news: —Green Bay Packers quarterback Aaron Rodgers has a new title: venture capitalist. He co-founded and serves as general partner of Rx3 Ventures, a Newport Beach, CA-based firm that recently raised more than $50 million for its debut fund. The fund will make “venture and … Continue reading “WI Watchlist: Aaron Rodgers, Redox, Zywave, Rusinow & More”

Big Business Has Your Data, and Osano Is Rating How They Handle It

Austin—Anyone who has an Evite account may be a bit wary right now: The company confirmed this month that personal data of some of its users, including names, dates of birth, and mailing addresses, were stolen. Some folks may have changed their password (recommended!), while others may have deleted their accounts to say good riddance. … Continue reading “Big Business Has Your Data, and Osano Is Rating How They Handle It”

Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More

Is one of the bigger biopharma acquisitions of the year in trouble? This past week, antitrust regulators once again delayed Roche’s planned $4.8 billion buyout of gene therapy developer Spark Therapeutics (NASDAQ: [[ticker:ONCE]]). The US Federal Trade Commission wants yet more information about the buyout, and overseas, the UK Competition and Markets Authority opened a … Continue reading “Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More”

Gener8tor to Make Startups From Scratch in Revamped Milwaukee Program

[Updated 6/14/19, 10:25 am CT. See below.] Gener8tor, a Wisconsin-based organization with a growing network of startup accelerators across the Midwest, is shaking up the format of its flagship Milwaukee program in a bid to catalyze entrepreneurship among locals. Instead of seeking applications from existing startups located around the world, this fall’s Gener8tor program in … Continue reading “Gener8tor to Make Startups From Scratch in Revamped Milwaukee Program”

IPO Scorecard: CrowdStrike Gains 70 Percent on First Trading Day

Cybersecurity firm CrowdStrike delivered the kind of market debut this week that was an unfulfilled dream for the much-anticipated IPOs of Uber and Lyft earlier this year. Sunnyvale, CA-based CrowdStrike (NASDAQ: [[ticker:CRWD]]) priced 18 million shares of common stock at $34 on Tuesday. Trading began at $63.50 Wednesday, and reached a near-doubling of the company’s … Continue reading “IPO Scorecard: CrowdStrike Gains 70 Percent on First Trading Day”

Polco’s Tools Help Governments Coax Citizens Out of Echo Chambers

[Updated 6/11/19, 7:31 am CT. See below.] Nick Mastronardi is finding success in countering the negative trend of endless partisan bickering by helping local governments gather public sentiments through online polling. Mastronardi (pictured above) is co-founder and CEO of Polco, a company based in Madison, WI, that he says is growing thanks to its ability to … Continue reading “Polco’s Tools Help Governments Coax Citizens Out of Echo Chambers”

3 Tips to Boost Security, Trust With Increasingly Remote Workforce

Employers are increasingly offering remote work options as a differentiator to attract top talent in today’s competitive hiring market. And, with modern technology at their fingertips, employees have come to expect a seamless working experience whether they’re home, in the office, or on the road. These new expectations, coupled with the increase of contract and … Continue reading “3 Tips to Boost Security, Trust With Increasingly Remote Workforce”

Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More

Welcome to conference week. That’s not an official moniker, but is there any busier time on the biopharma calendar? As the American Society of Clinical Oncology meeting wrapped up in Chicago, the annual BIO conference kicked off in Philadelphia, and a deep dive into diabetes begins today in San Francisco. With half the biopharma world, … Continue reading “Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More”

Rocket Engines & Startup Fuel: NM, Abodo, & More WI Headlines

It’s time to catch up on recent Wisconsin innovation news, including more funding for startups and expanded production of rocket engines in the Madison area. Read on for more details. —Northwestern Mutual said it’s pumping $150 million into its second in-house venture capital fund. The Milwaukee-based insurance and wealth management services giant invested $50 million … Continue reading “Rocket Engines & Startup Fuel: NM, Abodo, & More WI Headlines”

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

The American Society of Clinical Oncology meeting in Chicago has wrapped up for another year. Last week, we featured two stories that you wouldn’t find at the ASCO frenzy: Immunotherapy’s lack of progress in treating breast cancer, and one woman’s risky bet of tens of millions of dollars from her personal fortune to speed drug … Continue reading “ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More”

Apple Touts New Privacy Moves as Antitrust Probes Loom for Big Tech

Both the House leadership and the Trump administration are preparing to challenge the power of Google, Facebook, and other big tech companies by launching antitrust investigations into their allegedly anticompetitive business practices, as the Washington Post detailed it this week. But the growing concern about the pervasive control of tech giants in arenas such as … Continue reading “Apple Touts New Privacy Moves as Antitrust Probes Loom for Big Tech”

Study: Gene Edits in CRISPR Babies Could Boost Risk of Earlier Death

The Chinese scientist He Jiankui, who revealed last fall that he used CRISPR gene editing to try to make twin newborn girls immune to HIV infection, might have also given them a higher risk of death. That’s according to a new study from University of California, Berkeley data scientists who analyzed the records of more … Continue reading “Study: Gene Edits in CRISPR Babies Could Boost Risk of Earlier Death”

From Farm to (Financial) Table: Holt Ventures Partner Meg Paulus

San Antonio—Meg Paulus gets a sense of comfort when she walks around the campus of her work at Holt Cat, a San Antonio-based heavy equipment and engine dealer focused on Caterpillar tractors. Paulus grew up in rural southeast Wisconsin where she raised sheep and chickens and showed them off at annual 4-H fairs. Those memories … Continue reading “From Farm to (Financial) Table: Holt Ventures Partner Meg Paulus”

Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More

[Corrected 5/31/19, 8:48 am ET. See below.] Pharmaceutical companies that make or market opioids have found themselves in legal hot water, and much of the heat is coming from Oklahoma. This week, a trial began litigating Johnson & Johnson’s responsibility for opioid addiction in the Sooner State. Johnson & Johnson (NYSE: [[ticker:JNJ]]) entered the Norman, … Continue reading “Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More”

Quantum Computing 101: Brilliant, Google, Microsoft Training Workers

From Microsoft and IBM to Alphabet’s unit X and Canada’s D-Wave Systems, companies are racing to build powerful quantum computers that may solve problems beyond the capacity of the most sophisticated conventional processors, and do it much faster. It’ll be some years before such uber-computers are robust and reliable enough for broad commercial use. But … Continue reading “Quantum Computing 101: Brilliant, Google, Microsoft Training Workers”

Agenda Posted for Net@50 on July 16 at MIT Media Lab

Come celebrate milestones the internet has made over the past 50 years at a special event called Net@50 on July 16 in Cambridge, MA, organized by the World Frontiers Forum and Xconomy. An afternoon forum at the MIT Media Lab will explore the big issues and challenges surrounding the internet. And a gala dinner at … Continue reading “Agenda Posted for Net@50 on July 16 at MIT Media Lab”

Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?

When the brain goes bad, modern medicine is often powerless to help. That’s the case for Alzheimer’s disease, where drug after drug has failed, and the only approved treatments are marginally helpful at best. The same seems increasingly clear for the most common and aggressive type of brain cancer, glioblastoma multiforme. Its origins are mysterious, … Continue reading “Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?”

Immunotherapy Is Now Here For Breast Cancer. What Are Its Prospects?

Drugs that rev up a patient’s immune system have changed how we treat cancers of the skin, lung, and more, offering people whose tumors have spread a chance to live longer than ever thought possible. But until this year, the field had nothing for breast cancer, which kills more women than any other cancer type. … Continue reading “Immunotherapy Is Now Here For Breast Cancer. What Are Its Prospects?”

Second US Gene Therapy, Approved for Rare Muscle Disease, to Cost $2M

The FDA today has made Zolgensma, a Novartis treatment for the rare genetic disease spinal muscular atrophy, the second approved gene therapy in the US. The news marks a milestone for SMA patients, who have only one other approved medicine available. But it comes with a cost: At $2.125 million, Zolgensma’s price tag creates a … Continue reading “Second US Gene Therapy, Approved for Rare Muscle Disease, to Cost $2M”

Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma, a Novartis (NYSE: [[ticker:NVS]]) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio, Zolgensma will be a litmus test for the nascent field. If approved this week or next, it … Continue reading “Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More”

Despite Industrial Tech’s Growing Sophistication, US Adoption Lags

This week, Detroit is hosting SME’s RAPID + TCT event, a conference and trade show dedicated to additive manufacturing, commonly known as 3D printing. It’s the first time the conference, which draws attendees from across the world, has been held in Detroit since 2014. Maria Conrado, SME’s senior event manager, says the conference has grown … Continue reading “Despite Industrial Tech’s Growing Sophistication, US Adoption Lags”